Spero Therapeutics, Inc.
NASDAQ:SPROBiotechnology
+$0.08 today
- Market cap
- $50.92M
- Beta
- 1.46
- P/E (TTM)
- 8.2
- EPS (TTM)
- $0.27
Volume 0.27M
Average 0.78M
SPRO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Spero Therapeutics, Inc.NASDAQ: SPRO
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$16K, compared with $2.42M a year earlier. Trailing-twelve-month accounts receivables was $624K. Over 3 fiscal years it compounded at +25.5% a year.
Context
- Accounts receivables amounted to 5.1% of revenue in FY2025, up 1.9 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$16K or moves back toward the trailing-twelve-month quarterly average of $156K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 3.06M USD
- Year-over-year change
- +298.5%
- 4-year CAGR
- -5.5%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.06M | +298.5% |
| FY2024 | 2024-12-31 | (1.54M) | -234.1% |
| FY2023 | 2023-12-31 | (461K) | -129.8% |
| FY2022 | 2022-12-31 | 1.55M | -59.6% |
| FY2021 | 2021-12-31 | 3.83M | — |
Accounts Receivables vs competitors
How SPRO compares with its peers on the latest reported figures
- SPRO's LTM Mar 2026 accounts receivables of $624K is the 5th largest of the 10 companies compared; the peer median is $331.65K.
- Its year-over-year change of -85.7% is the lowest of 6, against a peer median of +128.6%.
- Accounts receivables amounts to 1.1% of revenue for SPRO, versus a peer median of 17.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.53M | +162.9% | — | 220.4% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $2.04M | +224.6% | — | 17.0% |
| LTM Mar 2026 | $1.12M | +128.6% | +72.7% | — | |
| LTM Mar 2026 | $1.1M | +37.9% | — | 7.3% | |
| LTM Mar 2026 | $624K | -85.7% | +25.5% | 1.1% | |
| LTM Mar 2026 | $331.65K | -73.3% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding SPRO) | $331.65K | +128.6% | +72.7% | 17.0% | |
Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (89.76M) | (46.42M) | 22.81M | (68.57M) | 8.57M |
| Depreciation & Amortization | 1.12M | 869K | 367K | 2K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.43M | 9.12M | 7.93M | 7.79M | 4.33M |
| Change in Working Capital | 12.86M | 22.09M | (70.38M) | 36.28M | (27.16M) |
| Accounts Receivables | 3.83M | 1.55M | (461K) | (1.54M) | 3.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (53K) | (484K) | 761K | 5.93M | (6.61M) |
| Other Working Capital | 9.08M | 21.02M | (70.68M) | 31.9M | (23.6M) |
| Other Non-Cash Items | 11.43M | 6.61M | 6.28M | 1.04M | 1.64M |
| Operating Cash Flow | (64.35M) | (7.73M) | (33M) | (23.44M) | (12.62M) |
| Capital Expenditures | 64.35M | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 39K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (43.92M) | (26.97M) | 0 | 0 | 0 |
| Sales of Investments | 51.55M | 60.78M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 7.67M | 33.81M | 0 | 0 | 0 |
| Debt Repayment | 47.48M | (54.49M) | 0 | 0 | 0 |
| Common Stock Issued | 36.57M | 24.93M | 221K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 84.05M | (29.55M) | 221K | 0 | 0 |
| Effect of Forex Changes | (1) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 27.38M | (3.48M) | (32.77M) | (23.44M) | (12.62M) |
| Free Cash Flow | (64.35M) | (7.73M) | (33M) | (23.44M) | (12.62M) |
Spero Therapeutics, Inc.
NASDAQ:SPRO
Intrinsic Alpha fair value
Locked
Current Price
$0.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.